Who
Aziz Mottiwala
President and CEO
Company insider
Files Form 4 as: President and CEO, RxSight; Chief Commercial Officer, Tarsus Pharmaceuticals.
In numbers
- Trades disclosed
- 72
- Buys
- 0
- Sells
- 24
- Bought
- $0
- Sold
- $3.8M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 7 Jan 2021
- Last trade
- 24 Jul 2026
- Last filed
- 24 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jul 2026filed 24 Jul 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,312,138 at $0.00 | filing |
| 24 Jul 2026filed 24 Jul 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code A | —571,286 at $0.00 | filing |
| 24 Jul 2026filed 24 Jul 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,312,138 at $0.00 | filing |
| 24 Jul 2026filed 24 Jul 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code A | —571,286 at $0.00 | filing |
| 19 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $297K4,440 at $67.00 | filing |
| 19 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $297K4,440 at $67.00 | filing |
| 18 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $298K4,330 at $68.71 | filing |
| 18 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $298K4,330 at $68.71 | filing |
| 17 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $298K4,286 at $69.42 | filing |
| 17 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $298K4,286 at $69.42 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —26,482 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,790 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,148 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,790 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,148 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,020 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,524 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,020 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,524 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —26,482 | filing |
News
Reviewing Tarsus Pharmaceuticals (NASDAQ:TARS) and Novo Nordisk A/S (NYSE:NVO)TARS · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Aziz Mottiwala; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.